XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update

Stock Information for XORTX Therapeutics

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About XORTX Therapeutics

XORTX Announces Closing of US$1.1 Million Registered Direct Offering
XORTX Announces Pricing of US$1.1 Million Registered Direct Offering
XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
Join XORTX for an Exclusive Live Investor Webinar and Q&A Session on September 10
XORTX Initiates IND Preparation for XORLO(TM) in Gout Program
XORTX Completes USD $114,500 Private Placement

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.